The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity
Open accessAbstract
Summary Immune checkpoint blockade (ICB) therapy frequently induces immune related adverse events. To elucidate the underlying immunobiology, we performed a deep immune analysis of intestinal, colitis, and tumor tissue from ICB-treated patients with parallel studies in preclinical models. Expression of interleukin-6 (IL-6), neutrophil and chemotactic markers was higher in colitis than in normal intestinal tissue; T helper 17 (Th17) cells were more prevalent in immune-related enterocolitis (irEC) than T helper 1 (Th1). Anti-cytotoxic T-lymphocyte-associated antigen 4 (anti-CTLA-4) induced stronger Th17 memory in colitis than anti-program death 1 (anti-PD-1). In murine models, IL-6 blockade associated with improved tumor control and a higher density of CD4+/CD8+ effector T cells, with reduced Th17, macrophages, and myeloid cells. In an experimental autoimmune encephalomyelitis (EAE) model with tumors, combined IL-6 blockade and ICB enhanced tumor rejection while simultaneously mitigating EAE symptoms versus ICB alone. IL-6 blockade with ICB could de-couple autoimmunity from antitumor immunity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Bettelli, E., Carrier, Y., Gao, W., Korn, T., Strom, T. B., Oukka, M., Weiner, H. L., & Kuchroo, V. K. (2006) · Nature · doi:10.1038/nature04753 · Cited by 6,992
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
Ivanov, I. I., McKenzie, B. S., Zhou, L., Tadokoro, C. E., Lepelley, A., Lafaille, J. J., Cua, D. J., & Littman, D. R. (2006) · Cell · doi:10.1016/j.cell.2006.07.035 · Cited by 5,145
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Postow, M. A., Sidlow, R., & Hellmann, M. D. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1703481 · Cited by 4,849
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
Motzer, R. J., Tannir, N. M., McDermott, D. F., Arén Frontera, O., Melichar, B., Choueiri, T. K., Plimack, E. R., Barthélémy, P., Porta, C., George, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1712126 · Cited by 4,656
Self-citationNivolumab plus ipilimumab in lung cancer with a high tumor mutational burden
Hellmann, M. D., Ciuleanu, T.-E., Pluzanski, A., Lee, J. S., Otterson, G. A., Audigier-Valette, C., Minenza, E., Linardou, H., Burgers, S., Salman, P., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801946 · Cited by 3,063
Wang, D. Y., Salem, J.-E., Cohen, J. V., Chandra, S., Menzer, C., Ye, F., Zhao, S., Das, S., Beckermann, K. E., Ha, L., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.3923 · Cited by 2,674
Self-citationIL-6 as a keystone cytokine in health and disease
Hunter, C. A., & Jones, S. A. (2015) · Nature Immunology · doi:10.1038/ni.3153 · Cited by 2,511
Curran, M. A., Montalvo, W., Yagita, H., & Allison, J. P. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0915174107 · Cited by 1,874
Self-citationCancer immunoediting and resistance to T cell-based immunotherapy
O’Donnell, J. S., Teng, M. W. L., & Smyth, M. J. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0142-8 · Cited by 1,759
Tumour-intrinsic resistance to immune checkpoint blockade
Kalbasi, A., & Ribas, A. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0218-4 · Cited by 1,486
Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
Weber, J. S., Kähler, K. C., & Hauschild, A. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.41.6750 · Cited by 1,415
Targeting IL-17 and TH17 cells in chronic inflammation
Miossec, P., & Kolls, J. K. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3794 · Cited by 1,414
Interleukin-17 and Type 17 Helper T Cells
Miossec, P., Korn, T., & Kuchroo, V. K. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0707449 · Cited by 1,409
Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade
Wei, S. C., Levine, J. H., Cogdill, A. P., Zhao, Y., Anang, N.-A. A. S., Andrews, M. C., Sharma, P., Wang, J., Wargo, J. A., Pe’er, D., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.024 · Cited by 1,302
Self-citationFate mapping of IL-17-producing T cells in inflammatory responses
Hirota, K., Duarte, J. H., Veldhoen, M., Hornsby, E., Li, Y., Cua, D. J., Ahlfors, H., Wilhelm, C., Tolaini, M., Menzel, U., et al. (2011) · Nature Immunology · doi:10.1038/ni.1993 · Cited by 1,176
Induction and molecular signature of pathogenic TH17 cells
Lee, Y., Awasthi, A., Yosef, N., Quintana, F. J., Xiao, S., Peters, A., Wu, C., Kleinewietfeld, M., Kunder, S., Hafler, D. A., et al. (2012) · Nature Immunology · doi:10.1038/ni.2416 · Cited by 1,174
Attia, P., Phan, G. Q., Maker, A. V., Robinson, M. R., Quezado, M. M., Yang, J. C., Sherry, R. M., Topalian, S. L., Kammula, U. S., Royal, R. E., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.205 · Cited by 1,012
IL-17 can promote tumor growth through an IL-6–Stat3 signaling pathway
Wang, L., Yi, T., Kortylewski, M., Pardoll, D. M., Zeng, D., & Yu, H. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20090207 · Cited by 842
Blank, C. U., Haanen, J. B., Ribas, A., & Schumacher, T. N. (2016) · Science · doi:10.1126/science.aaf2834 · Cited by 748
The Intermucosal Connection between the Mouth and Gut in Commensal Pathobiont-Driven Colitis
Kitamoto, S., Nagao-Kitamoto, H., Jiao, Y., Gillilland, M. G., Hayashi, A., Imai, J., Sugihara, K., Miyoshi, M., Brazil, J. C., Kuffa, P., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.048 · Cited by 680
Ito, H., Takazoe, M., Fukuda, Y., Hibi, T., Kusugami, K., Andoh, A., Matsumoto, T., Yamamura, T., Azuma, J., & Nishimoto, N. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.01.012 · Cited by 636
Single-cell genomics unveils critical regulators of Th17 cell pathogenicity
Gaublomme, J. T., Yosef, N., Lee, Y., Gertner, R. S., Yang, L. V., Wu, C., Pandolfi, P. P., Mak, T., Satija, R., Shalek, A. K., et al. (2015) · Cell · doi:10.1016/j.cell.2015.11.009 · Cited by 575
Yadav, A., Kumar, B., Datta, J., Teknos, T. N., & Kumar, P. (2011) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-11-0271 · Cited by 503
Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy
Luoma, A. M., Suo, S., Williams, H. L., Sharova, T., Sullivan, K., Manos, M., Bowling, P., Hodi, F. S., Rahma, O., Sullivan, R. J., et al. (2020) · Cell · doi:10.1016/j.cell.2020.06.001 · Cited by 484
Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy
Perez-Ruiz, E., Minute, L., Otano, I., Alvarez, M., Ochoa, M. C., Belsue, V., de Andrea, C., Rodriguez-Ruiz, M. E., Perez-Gracia, J. L., Marquez-Rodas, I., et al. (2019) · Nature · doi:10.1038/s41586-019-1162-y · Cited by 480
The experimental autoimmune encephalomyelitis (EAE) model of MS
(2014) · Handbook of Clinical Neurology · doi:10.1016/b978-0-444-52001-2.00008-x · Cited by 464
Il-23 secreted by myeloid cells drives castration-resistant prostate cancer
Calcinotto, A., Spataro, C., Zagato, E., Di Mitri, D., Gil, V., Crespo, M., De Bernardis, G., Losa, M., Mirenda, M., Pasquini, E., et al. (2018) · Nature · doi:10.1038/s41586-018-0266-0 · Cited by 394
Tc17, a Unique Subset of CD8 T Cells That Can Protect against Lethal Influenza Challenge
Hamada, H., Garcia-Hernandez, M. D. L. L., Reome, J. B., Misra, S. K., Strutt, T. M., McKinstry, K. K., Cooper, A. M., Swain, S. L., & Dutton, R. W. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0801814 · Cited by 387
Moving towards personalized treatments of immune-related adverse events
Esfahani, K., Elkrief, A., Calabrese, C., Lapointe, R., Hudson, M., Routy, B., Miller, W. H., & Calabrese, L. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0352-8 · Cited by 351
Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade
Stroud, C. R., Hegde, A., Cherry, C., Naqash, A. R., Sharma, N., Addepalli, S., Cherukuri, S., Parent, T., Hardin, J., & Walker, P. (2019) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155217745144 · Cited by 331
Heterogeneity in the Differentiation and Function of CD8+ T Cells
Mittrücker, H.-W., Visekruna, A., & Huber, M. (2014) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-014-0293-y · Cited by 325
Dulos, J., Carven, G. J., van Boxtel, S. J., Evers, S., Driessen-Engels, L. J. A., Hobo, W., Gorecka, M. A., de Haan, A. F. J., Mulders, P., Punt, C. J. A., et al. (2012) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318247a4e7 · Cited by 316
van Elsas, A., Sutmuller, R. P. M., Hurwitz, A. A., Ziskin, J., Villasenor, J., Medema, J.-P., Overwijk, W. W., Restifo, N. P., Melief, C. J. M., Offringa, R., et al. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.4.481 · Cited by 309
Self-citationSznol, M., Ferrucci, P. F., Hogg, D., Atkins, M. B., Wolter, P., Guidoboni, M., Lebbé, C., Kirkwood, J. M., Schachter, J., Daniels, G. A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.72.1167 · Cited by 286
T-bet Regulates the Fate of Th1 and Th17 Lymphocytes in Autoimmunity
Gocke, A. R., Cravens, P. D., Ben, L.-H., Hussain, R. Z., Northrop, S. C., Racke, M. K., & Lovett-Racke, A. E. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.3.1341 · Cited by 250
Sharma, P., Siefker-Radtke, A., de Braud, F., Basso, U., Calvo, E., Bono, P., Morse, M. A., Ascierto, P. A., Lopez-Martin, J., Brossart, P., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00538 · Cited by 243
Self-citationCurrent Views on the Roles of Th1 and Th17 Cells in Experimental Autoimmune Encephalomyelitis
El-behi, M., Rostami, A., & Ciric, B. (2010) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-009-9188-9 · Cited by 219
Valpione, S., Pasquali, S., Campana, L. G., Piccin, L., Mocellin, S., Pigozzo, J., & Chiarion-Sileni, V. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-018-1467-x · Cited by 201
Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis
Abu-Sbeih, H., Ali, F. S., Naqash, A. R., Owen, D. H., Patel, S., Otterson, G. A., Kendra, K., Ricciuti, B., Chiari, R., De Giglio, A., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00320 · Cited by 199
Self-citationA role for Th1-like Th17 cells in the pathogenesis of inflammatory and autoimmune disorders
Kamali, A. N., Noorbakhsh, S. M., Hamedifar, H., Jadidi-Niaragh, F., Yazdani, R., Bautista, J. M., & Azizi, G. (2019) · Molecular Immunology · doi:10.1016/j.molimm.2018.11.015 · Cited by 194
CTLA4 blockade increases Th17 cells in patients with metastatic melanoma
von Euw, E., Chodon, T., Attar, N., Jalil, J., Koya, R. C., Comin-Anduix, B., & Ribas, A. (2009) · Journal of Translational Medicine · doi:10.1186/1479-5876-7-35 · Cited by 189
Neurologic complications of immune checkpoint inhibitors
Haugh, A. M., Probasco, J. C., & Johnson, D. B. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1738382 · Cited by 187
Self-citationSilencing T-bet Defines a Critical Role in the Differentiation of Autoreactive T Lymphocytes
Lovett-Racke, A. E., Rocchini, A. E., Choy, J., Northrop, S. C., Hussain, R. Z., Ratts, R. B., Sikder, D., & Racke, M. K. (2004) · Immunity · doi:10.1016/j.immuni.2004.09.010 · Cited by 183
Rai, D., Pham, N.-L. L., Harty, J. T., & Badovinac, V. P. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0902874 · Cited by 172
Bittner, S., Afzali, A. M., Wiendl, H., & Meuth, S. G. (2014) · Journal of Visualized Experiments · doi:10.3791/51275 · Cited by 171
Successful treatment of arthritis induced by checkpoint inhibitors with tocilizumab: a case series
Kim, S. T., Tayar, J., Trinh, V. A., Suarez-Almazor, M., Garcia, S., Hwu, P., Johnson, D. H., Uemura, M., & Diab, A. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2017-211560 · Cited by 170
Self-citationBasdeo, S. A., Cluxton, D., Sulaimani, J., Moran, B., Canavan, M., Orr, C., Veale, D. J., Fearon, U., & Fletcher, J. M. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1600737 · Cited by 161
Ogata, A., Tanimura, K., Sugimoto, T., Inoue, H., Urata, Y., Matsubara, T., Kondo, M., Ueki, Y., Iwahashi, M., Tohma, S., et al. (2014) · Arthritis Care & Research · doi:10.1002/acr.22110 · Cited by 140
Tanaka, R., Okiyama, N., Okune, M., Ishitsuka, Y., Watanabe, R., Furuta, J., Ohtsuka, M., Otsuka, A., Maruyama, H., Fujisawa, Y., et al. (2016) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2016.12.019 · Cited by 129
Evaluation of serum IL-17 levels during ipilimumab therapy: Correlation with colitis.
Callahan, M. K., Yang, A., Tandon, S., Xu, Y., Subudhi, S. K., Roman, R., Heine, A. I., Pogoriler, E., Kuk, D., Panageas, K., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.2505 · Cited by 129
Self-citationMasopust, D., Murali-Krishna, K., & Ahmed, R. (2007) · Journal of Virology · doi:10.1128/jvi.01459-06 · Cited by 114
Godbout, J., Berg, B. M., Kelley, K. W., & Johnson, R. W. (2004) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2003.12.017 · Cited by 107
Immunological Characteristics of Colitis Associated with Anti-CTLA-4 Antibody Therapy
Bamias, G., Delladetsima, I. K., Perdiki, Μ., Siakavellas, S. I., Goukos, D., Papatheodoridis, G., Daikos, G. L., & Gogas, H. J. (2017) · Cancer Investigation · doi:10.1080/07357907.2017.1324032 · Cited by 103
Cancer vaccine formulation dictates synergy with CTLA-4 and PD-L1 checkpoint blockade therapy
Hailemichael, Y., Woods, A. N., Fu, T., He, Q., Nielsen, M. C., Hasan, F., Roszik, J., Xiao, Z., Vianden, C., Khong, H., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci93303 · Cited by 84
Self-citationTajima, M., Wakita, D., Satoh, T., Kitamura, H., & Nishimura, T. (2011) · International Immunology · doi:10.1093/intimm/dxr086 · Cited by 80
Hurwitz, A. A., Sullivan, T. J., Sobel, R. A., & Allison, J. P. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.042684699 · Cited by 79
Self-citationUemura, M. I., Trinh, V. A., Haymaker, C., Jackson, N. A., Kim, D. W., Allison, J. P., Sharma, P., Vence, L. M., Bernatchez, C., Hwu, P., et al. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0309-7 · Cited by 69
Self-citationAbromson‐Leeman, S. R., Bronson, R. T., & Dorf, M. E. (2009) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2009.07.007 · Cited by 65
Kowalski, B., Valaperti, A., Bezel, P., Steiner, U. C., Scholtze, D., Wieser, S., Eisenring, M., Widmer, A., Kohler, M., & Franzen, D. (2021) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-021-03750-z · Cited by 61
Duo, C.-C., Gong, F., He, X.-Y., et al. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15022916 · Cited by 47
Anderson, R., & Rapoport, B. L. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00080 · Cited by 46
Fang, S., Zhang, S., Huang, Y., Wu, Y. R., Lu, Y. C., Zhong, S., Liu, X., Wang, Y., Li, Y., Sun, J. P., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa124 · Cited by 46
Self-citationDupilumab for Atopic Dermatitis: The Silver Bullet We Have Been Searching for?
Tameez‐ud‐din, A., Malik, I. J., Arshad, D., & Din, A. T. U. (2020) · Cureus · doi:10.7759/cureus.7565 · Cited by 33
The differentiation and plasticity of Tc17 cells are regulated by CTLA-4-mediated effects on STATs
Arra, A., Lingel, H., Kuropka, B., Pick, J., Schnoeder, T. M., Fischer, T., Freund, C., Pierau, M., & Brunner-Weinzierl, M. C. (2017) · OncoImmunology · doi:10.1080/2162402x.2016.1273300 · Cited by 26
Cited by
Targeting cytokine and chemokine signaling pathways for cancer therapy
Yi, M., Li, T., Niu, M., Zhang, H., Wu, Y., Wu, K., & Dai, Z. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01868-3 · Cited by 455
Managing the TME to improve the efficacy of cancer therapy
Bilotta, M. T., Antignani, A., & Fitzgerald, D. J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.954992 · Cited by 309
Halsey, T. M., Thomas, A. S., Hayase, T., Ma, W., Abu-Sbeih, H., Sun, B., Parra, E. R., Jiang, Z.-D., DuPont, H. L., Sanchez, C., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.abq4006 · Cited by 161
Self-citationGao, Y., Xu, P., Sun, D., Jiang, Y., Lin, X.-L., Han, T., Yu, J., Sheng, C., Chen, H., Hong, J., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-23-0605 · Cited by 116
Predictive Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Events
Les, I., Martínez, M., Pérez-Francisco, I., Cabero, M., Teijeira, L., Arrazubi, V., Torrego, N., Campillo-Calatayud, A., Elejalde, I., Kochan, G., et al. (2023) · Cancers · doi:10.3390/cancers15051629 · Cited by 100
Metadata
- Authors
- Hailemichael, Y., Johnson, D. H., Abdel-Wahab, N., Foo, W. C., Bentebibel, S.-E., Daher, M., Haymaker, C., Wani, K., Saberian, C., Ogata, D., Kim, S. T., Nurieva, R., Lazar, A. J., Abu-Sbeih, H., Fa'ak, F., Mathew, A., Wang, Y., Falohun, A., Trinh, V., Zobniw, C., Spillson, C., Burks, J. K., Awiwi, M., Elsayes, K., Soto, L. S., Melendez, B. D., Davies, M. A., Wargo, J., Curry, J., Yee, C., Lizee, G., Singh, S., Sharma, P., Allison, J. P., Hwu, P., Ekmekcioglu, S., & Diab, A.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2022-05
- Volume
- 40
- Issue
- 5
- Pages
- 509-523.e6
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W4229365571
- Cited by
- 359
- References
- 67
- FWCI
- 27.10
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.